Multiple Myeloma (MM)Phase 2BEYOND-MM 002NCT07903636
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
A Phase 2 study testing QLS4131 in people with Multiple Myeloma (MM), run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
Trial summary
This is a prospective, single-arm, phase II clinical trial evaluating the efficacy and safety of QLS4131 in patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma (MM)
- What is being tested?
- QLS4131
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2026to 1 Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Participants who are aware of and voluntarily sign the informed consent form (ICF), aged ≥18 years at the time of signing the ICF; male or female.
- 2. ECOG performance status of 0-2. 3. Diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, and meeting the following criteria:
- Received at least 1 line of systemic anti-myeloma therapy, previously exposed to proteasome inhibitors (PI), immunomodulatory drugs (IMiD), and anti-CD38 monoclonal antibodies, and refractory to the most recent line of therapy or progressed within the specified time after completion of the most recent line of therapy;
- Extramedullary disease identified by imaging examination, including the following two categories:
- True extramedullary disease (true EMD): soft tissue or organ plasmacytoma not contiguous with bone, with at least one lesion measuring ≥2 cm in the longest diameter;
- Paraskeletal disease (PSD): lesions formed by extension of bone lesions through the cortical bone into adjacent soft tissue, with at least one lesion measuring ≥5 cm in the longest diameter, or more than 2 paraskeletal lesions measuring ≥2 cm in the longest diameter.
Show all 13Show fewer
- 4. Participants who have previously received CAR-T cell therapy or bispecific antibody therapy are allowed. For participants who have previously received BCMA- or GPRC5D-targeted therapy, prior targeted therapy must involve only one of the targets, BCMA or GPRC5D. The interval from CAR-T cell infusion to the first administration of study drug must be ≥3 months, and the interval from the last dose of bispecific antibody to the first administration of study drug must be ≥28 days.
- 5. Participants without measurable hematologic disease are allowed to enroll. Measurable hematologic disease is defined as meeting any one or more of the following criteria:
- <!-- -->
- Serum M protein level ≥1.0 g/dL;
- Urine M protein level ≥200 mg/24 hours;
- Serum free light chain level ≥10 mg/dL with an abnormal serum free light chain ratio.
- 6. Adequate organ function. 7. Participants must voluntarily participate and be able to complete the study procedures and follow-up examinations.
Who cannot join
- Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or primary/secondary plasma cell leukemia.
- Central nervous system involvement or clinical evidence of meningeal involvement.
- Previous treatment with simultaneous BCMA and GPRC5D targeting therapies, including separate treatment targeting BCMA and GPRC5D, or treatment with dual-target BCMA and GPRC5D therapies.
- Radiotherapy: In principle, participants should not have received radiotherapy within 3 months before enrollment. If the lesion has previously received radiotherapy, radiographic evidence of clear progression after radiotherapy is required before it can be considered a baseline target lesion.
- Severe and/or uncontrolled cardiac disease.
- Major surgery within 4 weeks before the first administration of study drug, or planned major surgery during the study period.
Show all 11Show fewer
- Active infection, including HIV infection, active hepatitis B (HBV-DNA positive), active hepatitis C (HCV-RNA positive), active or latent syphilis, active tuberculosis, or other active infections considered unsuitable by the investigator.
- Concurrent other malignancies; or serious concomitant diseases that, in the investigator's assessment, seriously threaten participant safety or affect completion of the study.
- Pregnant or breastfeeding women.
- History of severe allergy or hypersensitivity to study drug components.
- Any other conditions that, in the investigator's judgment, make the participant unsuitable for enrollment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, 300000
Tianjin
Gang An, PhD&MD, 008613502181109, angang@ihcams.ac.cn
About this study
Official title: A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
This is a prospective, single-arm, phase II clinical trial evaluating the efficacy and safety of QLS4131 in patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD).
- Conditions
- Multiple Myeloma (MM)
- Being tested
- QLS4131
- Keywords
- extramedullary multiple myeloma, QLS4131
- Medical subject headings
- Multiple Myeloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QLS4131Drug
Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles.
| Study group | Role | What they receive |
|---|---|---|
| QLS4131 | Experimental | Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles. Receives: Drug: QLS4131 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Response Rate (ORR)
Measured: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Secondary outcomes (8)
Extramedullary Disease Objective Response Rate (EMD-ORR)
Measured: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Very Good Partial Response or Better Rate (≥VGPR Rate)
Measured: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Complete Response or Stringent Complete Response Rate (CR/sCR Rate)
Measured: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Time to Response (TTR)
Measured: From the first dose to the date of the first documented overall response of PR or better, assessed through the end of Cycle 24 (each cycle is 28 days).
Duration of Response (DoR)
Measured: From the date of the first documented overall response of PR or better to the date of disease progression or death from any cause, whichever occurs first, with follow-up through 12 months after the last dose.
Progression-Free Survival (PFS)
Measured: From the date of the first dose to the date of disease progression or death from any cause, whichever occurs first, with follow-up through 12 months after the last dose.
Overall Survival (OS)
Measured: From the date of the first dose to the date of death from any cause, with follow-up through 12 months after the last dose.
Incidence and Severity of Adverse Events (AEs)
Measured: Up to 2 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study start1 Dec 2026 (estimated)
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple Myeloma (MM)Studies of the same condition, open and under way.
- More trials run by Institute of Hematology & Blood Diseases Hospital, ChinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07903636
- Sponsor's protocol ID
- IIT2026113
- Acronym
- BEYOND-MM 002
- Status last verified
- Oct 2026
- First submitted
- 23 Oct 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- ClinicalTrials.gov ID
- NCT07903636
- Acronym / sponsor ID
- BEYOND-MM 002 / IIT2026113
- Conditions
- Multiple Myeloma (MM)
- Keywords
- extramedullary multiple myeloma, QLS4131
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaUniversity, hospital or other
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, single-arm, phase II clinical trial evaluating the efficacy and safety of QLS4131 in patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| QLS4131 | Experimental | Drug: QLS4131Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- 1. Participants who are aware of and voluntarily sign the informed consent form (ICF), aged ≥18 years at the time of signing the ICF; male or female.
- 2. ECOG performance status of 0-2. 3. Diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, and meeting the following criteria:
- Received at least 1 line of systemic anti-myeloma therapy, previously exposed to proteasome inhibitors (PI), immunomodulatory drugs (IMiD), and anti-CD38 monoclonal antibodies, and refractory to the most recent line of therapy or progressed within the specified time after completion of the most recent line of therapy;
- Extramedullary disease identified by imaging examination, including the following two categories:
- 4. Participants who have previously received CAR-T cell therapy or bispecific antibody therapy are allowed. For participants who have previously received BCMA- or GPRC5D-targeted therapy, prior targeted therapy must involve only one of the targets, BCMA or GPRC5D. The interval from CAR-T cell infusion to the first administration of study drug must be ≥3 months, and the interval from the last dose of bispecific antibody to the first administration of study drug must be ≥28 days.
Key exclusion criteria (11 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QLS4131Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles. | Drug | QLS4131 |
Primary outcome
Overall Response Rate (ORR)
Time frame: From the first dose to the end of Cycle 24 (each cycle is 28 days).
8 secondary outcomes
Extramedullary Disease Objective Response Rate (EMD-ORR)
Time frame: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Very Good Partial Response or Better Rate (≥VGPR Rate)
Time frame: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Complete Response or Stringent Complete Response Rate (CR/sCR Rate)
Time frame: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Time to Response (TTR)
Time frame: From the first dose to the date of the first documented overall response of PR or better, assessed through the end of Cycle 24 (each cycle is 28 days).
Duration of Response (DoR)
Time frame: From the date of the first documented overall response of PR or better to the date of disease progression or death from any cause, whichever occurs first, with follow-up through 12 months after the last dose.
Progression-Free Survival (PFS)
Time frame: From the date of the first dose to the date of disease progression or death from any cause, whichever occurs first, with follow-up through 12 months after the last dose.
Overall Survival (OS)
Time frame: From the date of the first dose to the date of death from any cause, with follow-up through 12 months after the last dose.
Incidence and Severity of Adverse Events (AEs)
Time frame: Up to 2 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Myeloma (MM)
RecruitingPhase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
High Risk Smoldering Multiple Myeloma (HR-SMM)
RecruitingPhase 1
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
AML, Multiple Myeloma
Not yet recruitingPhase 1
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Multiple Myeloma or Plasmacytoma
RecruitingPhase 1
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Myeloma, Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing QLS4131 in people with Multiple Myeloma (MM), run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gang An, PhD&MD (13502181109, angang@ihcams.ac.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Response Rate (ORR) (time frame: From the first dose to the end of Cycle 24 (each cycle is 28 days).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.